Drug Trial Radar · NCT04138849
Evaluate Safety, Pharmacokinetics and Pharmacodynamics of BBT-877 in Healthy Japanese Male
Last checked: Nov 19, 2026Latest source record: Jan 18, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Oct 1, 2019
Primary completion
Oct 25, 2019
Study completion Oct 25, 2019
Sponsor
- Lead sponsor
- Bridge Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- KCRN Research, LLC
- First posted
- Oct 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will collect safety, pharmacokinetic, and pharmacodynamic data in Japanese male subjects in order to support development worldwide.
Conditions
- Healthy Participants
Interventions
BBT-877 single doseDrug
Oral capsule, single dose.
Placebo single doseDrug
Oral capsule, single dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs)Time frame: Up to Day 14.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
WCCT
Cypress, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.